Biden will move to have Medicare, Medicaid cover GLP-1 weight-loss meds

Contributing sentiments towards policy:

60% : However, allowing eligible patients coverage for the meds would cost Medicare $25 billion over a decade and Medicaid $11 billion, Brooks-LaSure told the Times.
56% : However, any rule widening access to Wegovy and Zepbound via Medicare or Medicaid to anyone struggling with obesity would be ideal, Brooks-LaSure said.
52% : As well, many people who have obesity also have other chronic diseases -- such as diabetes or heart disease -- and Medicare and Medicaid already cover the drugs for people with these conditions.
49% : "We don't want to see people having to wait until they have these additional diseases before they get treatment," Chiquita Brooks-LaSure, the administrator of the Centers for Medicare and Medicaid Services (CMS), told The New York Times.
48% : According to CMS estimates, passage of the rule would open access to the weight-loss medications to 3.4 million potential new patients under Medicare and another 4 million under Medicaid.
47% : The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid.
45% : Right now, a law passed by Congress two decades ago prevents the Medicare and Medicaid from covering any "weight loss" drug.
37% : It's probable that the cost of Wegovy (made by Novo Nordisk) and Zepbound (made by Eli Lilly) would fall: The Biden administration has already passed legislation allowing Medicare to negotiate the price of Wegovy, starting in 2025.
15% : The Biden administration's proposal puts pressure on Trump and his team, who on their own may not have made such a move.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.